GAD2 and type 1 diabetes mellitus: This is despite the fact that radioimmunoassays have revealed that many APS1/APECED patients carry GAD65-reactive autoantibodies, a clinically applied biomarker for likely onset of T1D (Ziegler et al., 2013).